The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternative...
Guardado en:
Autores principales: | Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Pérez-Martínez, Manel Juan, Cristina Eguizabal |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4ba5c4420bbb41e9b71bdae59fe70e56 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Sergey Kulemzin, et al.
Publicado: (2021) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Erica L. Heipertz, et al.
Publicado: (2021) -
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
por: Zhengli Xu, et al.
Publicado: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021) -
The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors
por: Rodion A. Velichinskii, et al.
Publicado: (2021)